AstraZeneca announced that it has entered into an agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
The US Food and Drug Administration(FDA) has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.
After attending Shanghai CNEF and Hospitalar in Brazil you come home and look at the pile of name cards and the masses of client information you collected. Now what? We often establish new business relationships at exhibitions such as these but the key of securing them lies in how you follow up on your clients. Ddu (www.drugdu.com), the leading global pharmaceutical and medical device B2B online platform, today shares with you some insight on how to organize client materials and write your first follow up development letter. I. Organize and follow up on your clients with purpose The first step is to collect as much information as possible and pay special attention to all the relevant details at the exhibition. For example, what the client is looking for, what they are most concerned about, what kind of products and suppliers they have in mind and which business partners they would like to keep. After this you will be able to arrange the information according to clients’ interests ...
Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental New Drug Application (sNDA) for the use of TRISENOX® (arsenic trioxide) injection in combination with all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with newly diagnosed low or intermediate risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
According to a global statistics report on medical devices, the global surgical instruments market has witnessed a drastic growth spurt in the past 8 years. In 2010, global sales of surgical instruments reached 12 billion USD, 12.9 billion USD in 2011 and 18.6 billion USD in 2014.
Since the launch of the Ddu Global Promotion Plan, Ddu has succeeded in helping users do international product promotions without leaving home and has matched thousands of orders, rapidly gaining popularity in the medical trade industry. The upcoming exhibitions of Ddu’s Global Promotion Plan include Thailand, Vietnam, Azerbaijan and Argentina!
Apple is working with partners to test whether its smartwatch can be used to detect common heart conditions, an effort that would make its device a "must have" for millions of people worldwide. The company is partnering up with a group of clinicians at Stanford, as well as telemedicine vendor American Well, to test whether Apple Watch's heart rate sensor can detect abnormal heart rhythms in a cohort of patients, according to two people familiar. The people requested anonymity as these plans have not yet been made public.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.